Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.95 [0.87, 1.03]
5 studies · 1281 participants
Moderate

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

All‐cause mortality · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.94 [0.72, 1.23]
4 studies · 1060 participants
Low

Vitamin K antagonist (VKA) prophylaxis vs no prophylaxis

Mortality at 6 months: main analysis · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Vitamin K antagonist (VKA) prophylaxis showed no clear difference in mortality at 6 months: main analysis compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.93 [0.77, 1.13]
3 studies · 946 participants
Moderate